Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11486125 | 1.00 | KDM4E (0.60) | KDM4ERAB9AMAPTNPC1HSD17B10 | |
| SCHEMBL30837170 | 1.00 | KDM4E (0.60) | KDM4ERAB9AMAPTNPC1HSD17B10 | |
| SCHEMBL28492629 | 0.93 | KDM4E (0.57) | KDM4ERAB9AMAPTNPC1HSD17B10 | |
| SCHEMBL30383299 | 0.93 | KDM4E (0.53) | KDM4ERAB9AMAPTNPC1HSD17B10 | |
| SCHEMBL11471038 | 0.89 | HSD17B10 (0.67) | KDM4ERAB9ANPC1HSD17B10ALDH1A1 | |
| SCHEMBL5685530 | 0.89 | HSD17B10 (0.67) | KDM4ERAB9ANPC1HSD17B10ALDH1A1 | |
| SCHEMBL2757691 | 0.89 | HSD17B10 (0.67) | KDM4ERAB9ANPC1HSD17B10ALDH1A1 | |
| SCHEMBL7638425 | 0.82 | HSD17B10 (0.65) | KDM4ERAB9ANPC1HSD17B10ALDH1A1 | |
| SCHEMBL28335947 | 0.82 | HSD17B10 (0.65) | KDM4ERAB9ANPC1HSD17B10ALDH1A1 | |
| SCHEMBL1761703 | 0.81 | ALDH1A1 (0.55) | KDM4ERAB9AMAPTNPC1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| EP-3298002-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-10584108-B2 | Therapeutic compounds and methods of use thereof | KUALITY HERBCEUTICS LLC (US) | 2020-03-10 | — | — | US | disclosed |
| US-20180134679-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| WO-2016185423-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016179587-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2016-11-10 | — | — | WO | disclosed |
| US-4239908-A | N-aralkenyl-N'-cyano-N\"-(heterocyclylthioalkyl)-guanidines | G.D. SEARLE & CO. (US) | 1980-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | KDM4E 649/4885RAB9A 1205/4885MAPT 3677/4885 |
| US-20180134679-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NQO1, VHL, XIAP | KDM4E 2216/4885RAB9A 3040/4885MAPT 3227/4885 |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | MAP3K19, MAP3K20, MAP3K1 | KDM4E 629/4885RAB9A 1211/4885MAPT 3638/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | KDM4E 629/4885RAB9A 1211/4885MAPT 3638/4885 |
| US-10584108-B2 | Therapeutic compounds and methods of use thereof | NQO1, VHL, XIAP | KDM4E 2216/4885RAB9A 3040/4885MAPT 3227/4885 |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | KDM4E 629/4885RAB9A 1211/4885MAPT 3638/4885 |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | KDM4E 649/4885RAB9A 1205/4885MAPT 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.